KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Average (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Equity Average for 14 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Equity Average rose 3.35% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 3.35% year-over-year, with the annual reading at $1.0 billion for FY2025, 7.16% up from the prior year.
  • Equity Average for Q4 2025 was $1.1 billion at Supernus Pharmaceuticals, roughly flat from $1.1 billion in the prior quarter.
  • The five-year high for Equity Average was $1.1 billion in Q3 2025, with the low at $749.7 million in Q1 2021.
  • Average Equity Average over 5 years is $910.9 million, with a median of $916.0 million recorded in 2023.
  • The sharpest move saw Equity Average grew 24.03% in 2021, then grew 2.91% in 2024.
  • Over 5 years, Equity Average stood at $813.2 million in 2021, then increased by 6.93% to $869.5 million in 2022, then rose by 5.45% to $916.9 million in 2023, then increased by 11.41% to $1.0 billion in 2024, then rose by 3.35% to $1.1 billion in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $1.1 billion, $1.1 billion, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.